Development and Implementation of Clinical Trial Protocol Templates at the National Institute of Allergy and Infectious Diseases

Abstract

Background A clinical research protocol document must reflect both sound scientific rationale as well as local, national and, when applicable, international regulatory and human subject protections requirements. These requirements originate from a variety of sources, undergo frequent revision and are subject to interpretation. Tools to assist clinical investigators in the production of clinical protocols could facilitate navigating these requirements and ultimately increase the efficiency of clinical research.

Purpose The National Institute of Allergy and Infectious Diseases (NIAID) developed templates for investigators to serve as the foundation for protocol development. These protocol templates are designed as tools to support investigators in developing clinical protocols.

Methods NIAID established a series of working groups to determine how to improve its capacity to conduct clinical research more efficiently and effectively. The Protocol Template Working Group was convened to determine what protocol templates currently existed within NIAID and whether standard NIAID protocol templates should be produced. After review and assessment of existing protocol documents and requirements, the group reached consensus about required and optional content, determined the format and identified methods for distribution as well as education of investigators in the use of these templates.

Results The templates were approved by the NIAID Executive Committee in 2006 and posted as part of the NIAID Clinical Research Toolkit [1] website for broad access. These documents require scheduled revisions to stay current with regulatory and policy changes.

Limitations The structure of any clinical protocol template, whether comprehensive or specific to a particular study phase, setting or design, affects how it is used by investigators. Each structure presents its own set of advantages and disadvantages. While useful, protocol templates are not stand-alone tools for creating an optimal protocol document, but must be complemented by institutional resources and support. Education and guidance of investigators in the appropriate use of templates is necessary to ensure a complete yet concise protocol document. Due to changing regulatory requirements, clinical protocol templates cannot become static, but require frequent revisions.

Get full access to this article

View all access options for this article.

References

National Institute of Allergy and Infectious Diseases , Trans NIAID Clinical Research Toolkit. Available at: http://www.3.niaid.nih.gov/research/resources/toolkit/ (accessed 12 March 2009).

Department of Health and Human Services , Office of Human Research Protections. Available at: www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm (accessed 12 March 2009).

US Food and Drug Administration , Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm (accessed 22 June 2009).

Treweek S. , McCormack K. , Abalos E. et al. PRACTIHC Collaboration. The Trial Protocol Tool: The PRACTIHC software tool that supported the writing of protocols for pragmatic randomized controlled trials. J Clin Epidemiol 2006; 59: 1127-33.

National Institute of Allergy and Infectious Diseases. Clinical Trials Protocol Templates. Available at: http://www.3.niaid.nih.gov/research/resources/toolkit/protocol/ (accessed 12 March 2009).

Van-Tull B. , Houston C. , Wilson R. et al. The development and implementation of a standard template for all Institutional Review Board (IRB) protocols at a comprehensive cancer center; Abstract presentation Society for Clinical Trials 1999. Available at: http://www.sctweb.org/abstracts/abstracts1999/abs30.pdf (accessed 03 December 2009).

Rozich JD , Howard RJ , Justeson JM et al. Standardization as a mechanism to improve safety in health care . Jt Comm J Qual Patient Saf 2004; 1: 5-14.

International Conference on Harmonisation Efficacy 6 Guideline for Good Clinical Practice. Available at: http://www.ich.org/cache/compo/276-254-1.html , (accessed 12 March 2009).

National Institute of Allergy and Infectious Diseases , DMID Clinical Research Policies and Standard Procedure Documents, DMID Interventional Protocol Template. Available at: http://www.3.niaid.nih.gov/research/resources/DMIDClinRsrch/protdev.htm, (accessed 12 March 2009).

10.

Department of Health and Human Services, Office of Human Research Protections. Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events. Available at: http://www.hhs.gov/ohrp/policy/AdvEvntGuid.htm , (accessed 12 March 2009).

11.

US Food and Drug Administration , Draft Guidance for Clinical Investigators, Sponsors and IRBs Adverse Event Reporting - Improving Human Subject Protection. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079753.pdf (accessed 22 June 2009).